Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
The main goal of this clinical trial is to test if adding pertuzumab (Perjeta), improves the
anticancer activity of the combination chemotherapy regimen of trastuzumab (Herceptin)
concomitant with paclitaxel, 5-fluorouracil, epirubicin, and cyclophosphamide (T-FEC). The
study will also test the safety of this therapy.